Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Nuclear Medicine Diagnostics Market CAGR Outlook And Future Development
The nuclear medicine diagnostics market has seen substantial expansion recently. This market is projected to expand from $7.88 billion in 2025 to $8.84 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.2%. Historically, this growth has been driven by factors such as the greater adoption of radioactive tracers in diagnostics, the proliferation of hospital-based nuclear medicine facilities, a heightened need for functional imaging, the widespread presence of technetium-based radiopharmaceuticals, and an increase in clinical research within nuclear medicine.
The nuclear medicine diagnostics market size is anticipated to expand rapidly in the coming years. It is projected to grow to $13.77 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The expansion during the forecast period can be attributed to several factors, including increasing investments in theranostics, the rising adoption of precision oncology diagnostics, the expansion of PET imaging infrastructure, a growing focus on targeted radiopharmaceutical development, and increasing regulatory support for nuclear diagnostics. Significant trends for the forecast period encompass the increasing adoption of PET-based diagnostic radiopharmaceuticals, a rising demand for personalized nuclear diagnostics, the growing integration of imaging and therapeutic applications, the expansion of oncology-focused nuclear medicine procedures, and an enhanced focus on short-half-life radiotracers.
Get A Free Sample Report With In-Depth Market Insights:
Nuclear Medicine Diagnostics Market Growth Catalysts And Demand Drivers
The rising occurrence of cancer is anticipated to fuel the expansion of the nuclear medicine diagnostics market moving forward. Cancer is defined as a collection of diseases characterized by the uncontrolled multiplication and spread of abnormal cells within the body, which can aggregate into a mass or lump known as a tumor. The growth in cancer prevalence stems from the global aging population, as cancer incidence significantly increases with age, coupled with improved healthcare extending life expectancy. Nuclear medicine diagnostics are employed in the detection, staging, and monitoring of various cancer types, containing radioactive substances that specialized cameras can detect to create detailed images of the internal structures and functions of organs and tissues. For instance, in May 2025, data from the National Cancer Institute, a US-based intergovernmental organization, indicated that in 2022, nearly 20 million people were diagnosed with cancer and 9.7 million died from it, with projections for 2050 showing these figures climbing to 33 million new cases and 18.2 million deaths annually. Therefore, the increasing number of cancer cases is driving the growth of the nuclear medicine diagnostics market.
Nuclear Medicine Diagnostics Market Segment Landscape And Growth Outlook
The nuclear medicine diagnostics market covered in this report is segmented –
1) By Type: SPECT Radiopharmaceuticals, PET Radiopharmaceuticals
2) By Application: Cardiology, Thyroid, Neurology, Oncology, Other Applications
3) By End-User: Hospitals And Diagnostic Centers, Research Institutes
Subsegments:
1) By SPECT Radiopharmaceuticals: Technetium-99m-Based Radiopharmaceuticals, Iodine-123-Based Radiopharmaceuticals, Thallium-201-Based Radiopharmaceuticals, Other SPECT Radiopharmaceuticals
2) By PET Radiopharmaceuticals: Fluorine-18-Based Radiopharmaceuticals, Carbon-11-Based Radiopharmaceuticals, Gallium-68-Based Radiopharmaceuticals, Other PET Radiopharmaceuticals
Nuclear Medicine Diagnostics Market Trends Shaping Long-Term Demand
Leading companies in the nuclear medicine diagnostics market are concentrating on introducing sophisticated solutions, such as advanced medical technologies, to achieve a competitive advantage. Advanced medical technologies represent cutting-edge innovations in the medical field, designed to enhance patient outcomes, improve the standard of care, and promote better health. For example, in August 2023, Gleneagles Hospital, a Malaysia-based entity offering medical and healthcare services, unveiled its Nuclear Medicine Unit. This nuclear medicine unit is a specialized department within a hospital or medical center, furnished with the most current technology and staffed by highly trained experts. This facility’s objective is to enable the early detection, accurate diagnosis, and effective treatment of conditions using nuclear medicine imaging techniques.
Nuclear Medicine Diagnostics Market Leading Companies And Competitive Benchmarking
Major companies operating in the nuclear medicine diagnostics market are Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp, Institute of Isotopes Co Ltd., Theragnostics Ltd., Eczacibasi-Monrol Nuclear Products Co.
View The Full Nuclear Medicine Diagnostics Market Report:
Nuclear Medicine Diagnostics Market Top Region By Revenue And Market Share
North America was the largest region in the nuclear medicine diagnostics market in 2025. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
